The purpose of this study was to evaluate the safety, tolerability, and efficacy of 12 weeks of treatment with sovaprevir, ACH-0143102, and ribavirin (RBV) in genotype-1 (GT-1), treatment-naive, hepatitis C virus (HCV) participants.

Inclusion Criteria:

• Chronic HCV infection.
• HCV GT-1.
• HCV ribonucleic acid > 10,000 international units/milliliter at screening.
• Female participants must be willing to use 2 effective methods of contraception, one of which must be a barrier method, during the dosing period and 6 months after the last dose of RBV. Females of childbearing potential must have a negative pregnancy test at screening and baseline.
• Male participants must be willing to use an effective barrier method of contraception throughout the dosing period and for 6 months.
• Signed and dated written informed consent form.
• Willing to participate in all study activities and all study requirements (including effective contraception) during the study period.
• Treatment-naïve participants were defined as those participants who have never received pegylated interferon, RBV, or a direct-acting anti-viral agent for the treatment of chronic HCV infection.
• A liver biopsy within the last 3 years without evidence of cirrhosis.

Exclusion Criteria:

• Body mass index > 36.0 kilograms/meter squared.
• Pregnant or nursing (lactating) female participants confirmed by a positive human chorionic gonadotropin laboratory test or contemplating pregnancy.
• Participation in any interventional clinical trial within 35 days prior to first study medication dose administration on Day 1.
• Known human immunodeficiency virus (HIV)-1 or HIV-2 infection/serology and/or positive hepatitis B surface antigen.
• Use of dietary supplements, grapefruit juice, herbal supplements, cytochrome P450 (CYP) 2C8 substrates, CYP3A4 inducers and inhibitors, P-glycoprotein inducers and substrates, organic-anion-transporting polypeptide inhibitors and substrates, and potent inducers of other CYP enzymes within 14 days prior to dosing through 7 days following completion of study medications.
• Clinically significant laboratory abnormality at screening (specified in protocol).
• Other forms of liver disease.
• History of severe or uncontrolled psychiatric disease.
• History of malignancy of any organ system, treated or untreated within the past 5 years.
• History of major organ transplantation.
• Use of bone marrow colony stimulating factor agents within 3 months prior to baseline.
• History of seizure disorder requiring ongoing medical therapy.
• History of known coagulopathy including hemophilia.
• History of hemoglobinopathy, including sickle cell anemia and thalassemia.
• History of immunologically mediated disease (specified in protocol).
• History of clinical evidence of significant chronic cardiac disease ( specified in protocol).
• Electrocardiogram with any clinically significant abnormality.
• Structural or functional cardiac abnormalities (specified in protocol).
• History of chronic obstructive pulmonary disease, emphysema, or other chronic lung disease.
• Participants currently abusing amphetamines, cocaine or opiates, or with ongoing alcohol abuse in the judgement of the investigator.

The analysis population for baseline characteristics was the safety population, defined as all randomized participants who received at least 1 dose of the study drug.

AE data were collected from enrollment into the study through end of treatment plus 24 weeks of follow-up.

Treatment-emergent AEs were summarized.